Patient death prompts FDA halt on Pfizer’s Duchenne gene therapy study
The entrance to a Pfizer office in Cambridge, Massachusetts
A patient treated with an experimental Pfizer gene therapy for Duchenne muscular dystrophy has died, leading the FDA to stop the clinical trial. The death is still under investigation, but the halt is one of several clinical holds to…
Source: medcitynews.com and Read More